HNB
CPRX

Huntington National Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

Huntington National Bank’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4K Sell
1,068
-96
-8% -$2.29K ﹤0.01% 1559
2025
Q4 		$27.2K Sell
1,164
-212
-15% -$4.72K ﹤0.01% 1480
2025
Q3 		$27.1K Sell
1,376
-57
-4% -$1.17K ﹤0.01% 1491
2025
Q2 		$31.1K Buy
1,433
+734
+105% +$17.3K ﹤0.01% 1420
2025
Q1 		$17K Buy
699
+559
+399% +$12.6K ﹤0.01% 1579
2024
Q4 		$2.92K Buy
140
+32
+30% +$687 ﹤0.01% 2162
2024
Q3 		$2.15K Hold
108
– – ﹤0.01% 2227
2024
Q2 		$1.67K Buy
108
+18
+20% +$280 ﹤0.01% 2211
2024
Q1 		$1.44K Hold
90
– – ﹤0.01% 2218
2023
Q4 		$1.51K Hold
90
– – ﹤0.01% 2132
2023
Q3 		$1.05K Hold
90
– – ﹤0.01% 2199
2023
Q2 		$1.21K Buy
+90
New +$1.29K ﹤0.01% 2134

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Huntington National Bank's CPRX Position: Q1 2026 in Review

Huntington National Bank reduced its Catalyst Pharmaceutical (CPRX) stake by 8.2% in Q1 2026, selling an estimated $2.29K and leaving 1,068 shares worth $26.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

Huntington National Bank first reported a position in CPRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $31.1K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Huntington National Bank held 1,068 shares of Catalyst Pharmaceutical worth $26.4K as of Q1 2026.
  • Huntington National Bank sold 96 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.29K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1559 holding.
  • Huntington National Bank first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • Huntington National Bank's Catalyst Pharmaceutical position peaked at $31.1K in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.